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A survey of U.S. stem cell scientists shows that uncertainty following the legal challenge to the Obama
Administration’s hESC research policy has negative scientific and economic impacts and affects a range
of stem cell scientists, not just those working with hESCs. The international implications of these results
are also discussed.One consequence of the ethical contro-
versy inspired by human embryonic
stem cell (hESC) research has been an
atypically uncertain policy environment.
For stem cell scientists in the United
States and, in particular, those scientists
working with hESCs, frequent policy
changes have made the years since these
cells were first derived (Thomson et al.,
1998) something of a roller coaster.
Similar challenges have faced stem cell
scientists around the world, as numerous
countries in Europe, South America, and
Asia, as well as the European Union as
a whole, have engaged in protracted
debates over stem cell policy (see Gott-
weis et al., 2009 for a discussion of global
stem cell policy debates).
In the United States, scientists have
faced several hESC policy changes (re-
viewed in Gottweis, 2010). First, following
a legal review, the Clinton Administration
adopted a policy in August 2000 that
permitted federal funding of hESC
research, but not the derivation of new
hESC lines (65 Fed. Reg. 51,975). Before
any grants could be funded, however,
the Bush Administration put this policy
on hold and President Bush announced
a new policy in August 2001 limiting
federal funding to research using hESC
lines derived prior to the date of his
speech. Although this policy remained in
place for nearly eight years, uncertainty
persisted. Congress, for instance, twice
passed legislation to overturn the
temporal restrictions central to the policy,
yetPresidentBushvetoedboth thesebills.
During the Bush Administration, stem
cell policy was frequently addressed at
the state level with some states support-
ing stem cell research and others restrict-
ing it, creating one of the many heteroge-132 Cell Stem Cell 8, February 4, 2011 ª2011neous ‘‘policy patchworks’’ that have
become typical of the field, even on an
international scale (Caulfield et al., 2009).
Supportive state policies aimed to pro-
vide a workaround for scientists affected
by federal funding restrictions, yet even
these programs were plagued by uncer-
tainty, as legal challenges and state
budget problems hindered their imple-
mentation. California’s stem cell program,
for instance, was delayed for nearly 2 and
a half years by litigation, causing difficul-
ties for scientists considering starting
new stem cell projects or moving to new
institutions. California’s funding is now
flowing and the state has awarded more
than $1 billion, yet the future of this
program remains uncertain as the end of
its 10 year term approaches (see Karmali
et al., 2010 for a recent review of state
stem cell funding).
More recently, at the federal level, the
Obama Administration adopted a new
stem cell research policy in July 2009
(74 Fed. Reg. 32,170), only to throw the
field into chaos when scientists realized
the limited number of hESC lines that
had been eligible for federal funding
during the Bush Administration were no
longer on the approved list and needed
to be reevaluated. Key hESC lines,
including the two most heavily studied
lines, have since been added to the
registry, but not before months of uncer-
tainty during which some scientists were
placed in the awkward position of
choosing to delay projects until their
preferred cell lines were approved or
switching to other lines and facing the
delays associated with reoptimizing
experimental protocols.
A legal challenge filed following the
promulgation of the Obama Administra-Elsevier Inc.tion’s policy adds additional uncertainty
to the field. This challenge claims that
the Obama Administration’s policy vio-
lates the Dickey-Wicker Amendment,
a rider added to the Department of Health
and Human Services appropriations bill
each year since fiscal year 1996. This
lawsuit received minimal attention from
the scientific community until August 23,
2010 when U.S. District Court Judge
Royce Lamberth granted the plaintiffs’
request for a preliminary injunction
barring implementation of the Obama
Administration’s policy pending the out-
come of the court case. This ruling led
the NIH to suspend funding and review
of pending hESC research proposals as
well as evaluation of new hESC lines
(see Gottweis, 2010 for a general discus-
sion, U.S. NIH Notice NOT-OD-10-126
for details). The Obama Administration
appealed and on September 9, 2010 the
U.S. Court of Appeals for the District of
Columbia enjoined the preliminary injunc-
tion, allowing the NIH to resume funding
hESC research while the case proceeded.
Both the ultimate outcome of this case
and the length of time before the outcome
is known are uncertain, placing some
scientists in the situation of checking the
news each day to determine the legal
status of their research (Harmon, 2010).
Although the ultimate outcome of the
litigation will depend on statutory interpre-
tation of the Dickey-Wicker Amendment,
much of the legal wrangling thus far has
focused on the issue of potential harm to
stem cell scientists associated with these
policy changes. In his ruling announcing
the injunction, Judge Lamberth con-
cluded that the plaintiffs—two adult
stem cell scientists—would ‘‘suffer irrepa-
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Figure 1. Impact of the Temporary Funding Ban and Ongoing Policy Uncertainty by Type of
Stem Cells Used
Stem cell scientists’ views of the impact of the temporary ban on federal funding on their research (A) and
the impact of the ongoing policy uncertainty on their future research plans (B) are shown, grouped by the
type of stem cells scientists use in their research. n = 370 respondents (85 who use only nonpluripotent
stem cells [Non-PSCs], 79 who use pluripotent stem cells but not hESCs [PSCs but not hESCs], and
206 who use hESCs). Respondents were provided with a brief description of the ongoing legal proceed-
ings and then asked about the impact of the temporary funding ban on their research and ongoing policy
uncertainty on their research plans. Chi-square testing found that differences among these groups were
statistically significant (ban: chi-statistic = 75.1, df = 6, p = 3.6e14; policy uncertainty: chi-statistic = 91.7,
df = 6, p = 1.3e17). See Table S1 for text of the survey questions.
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for limited federal research funding, while
the ruling ‘‘would not seriously harm ESC
researchers because the injunction would
simply preserve the status quo and would
not interfere with their ability to obtain
private funding for their research’’ (U.S.
District Court for the District of Columbia).
In its appeal, the Obama Administration
disagreed, arguing that the harm to the
plaintiffs was speculative and
‘‘cannot outweigh the disruption or ruin
of research into promising treatments for
the most debilitating illnesses and
injuries’’ caused by the preliminary injunc-
tion (U.S. Court of Appeals for the D.C.
Circuit).
Despite this ongoing legal debate in the
United States and the prevalence of
policy uncertainty in this field around the
world, relatively few empirical studies
address these issues. In order to begin
to fill this gap, this Forum reports
responses from 370 individuals who
participated in a survey of U.S. stem cell
scientists in November 2010 and
assesses the reported impact of the
preliminary injunction and ongoing uncer-
tainty about the future of federal funding
for hESC research on their work (see
Supplemental Information available online
for details of survey design and analysis
strategies employed). These data show
that both Judge Lamberth’s ruling and
the ongoing uncertainty have had a sub-
stantial impact on stem cell scientists
and illustrate that this impact extendsbeyond hESC scientists to affect, often
negatively, a larger group of stem cell
scientists.
Scientists reported the impact of the
temporary funding ban and ongoing
policy uncertainty on a four-point scale
ranging from no impact to substantial
impact and scientists who indicated that
they experienced an impact were asked
to briefly explain the impact (see Table
S1 for the text of the survey questions).
Figure 1 shows the responses for these
questions for three groups: (1) Scientists
who use hESCs in their research; (2)
scientists who do not use hESCS but do
use human induced pluripotent stem cells
(IPSCs), nonhuman embryonic stem cells,
or non-human IPSCs in their research;
and (3) scientists who use only nonpluri-
potent stem cells in their research. Scien-
tists working with hESCs were most likely
to report being impacted by the tempo-
rary ban. Approximately 75% of these
scientists reported an impact and 24% re-
ported a substantial impact. In addition,
41% of stem cell scientists not working
with hESCs reported that the temporary
ban impacted their research, and 13% of
these respondents indicated this impact
was either moderate or substantial.
Notably, among the 50 non-hESC scien-
tists who indicated they were impacted
by the ban and answered a free-text
question describing this impact, negative
impacts were much more common than
the positive impact envisioned by Judge
Lamberth in his ruling. In total, 45 ofCell Stem Cell 8these non-hESC scientist respondents
described negative impacts (e.g., hin-
dered collaborations, blocked review of
funding applications, and challenges re-
cruiting), two described positive impacts
(enhanced attractiveness and fundability
of non-hESC research), and three could
not be classified as clearly positive or
negative.
The impact of ongoing policy uncer-
tainty on stem cell scientists’ research
plans was more substantial than the
impact of the temporary funding ban.
Just under half of the hESC scientists
who participated in the survey indicated
that this uncertainty has a substantial
impact on their research plans and
another 28% of these scientists said
this uncertainty has a moderate impact.
In addition, 47% of scientists who
worked with pluripotent stem cells, but
not hESCs, and 22% of scientists
working only with nonpluripotent stem
cells also indicated that this uncertainty
has either a moderate or substantial
impact on their research plans.
To better understand the nature of
these impacts, the responses of the 235
scientists who provided a free-text
description of the impact of policy uncer-
tainty on their research plans were
analyzed (see Supplemental Information
for details). Table 1 shows the ten most
frequent impacts mentioned by these
respondents (see Table S2 for example
responses for each impact). Many of
these reported impacts affected the type
or quality of science that these scientists
conducted, by, for instance, changing
the types of stem cells they used in their
research. The single most common
impact—mentioned by 50 respon-
dents—was delaying plans to begin
hESC research or start a new hESC
research project. Over 80% of the
respondents reporting this impact did
not currently work with hESCs but were
considering transitioning their research
to use these cells. In addition, 34 scien-
tists identified transitioning away from or
reducing reliance on hESCs as an impact
of the ongoing uncertainty. Not all of these
scientists specified the type of research to
which they were transitioning, but 13 indi-
cated that they were shifting their
research to human IPSCs or nonhuman
embryonic stem cells, even if, as might
be the case, these were less appropriate
tools for their specific research questions., February 4, 2011 ª2011 Elsevier Inc. 133







Delay plans to begin hESC research or new hESC project 50 18%
Impede ongoing research 44 16%
Limit future funding options 37 13%
Transition away from or reduce reliance on hESCs 34 12%
Disrupt long-term planning (e.g., hiring decisions) 24 9%
Adopt suboptimal research designs 19 7%
Delay or abandon NIH proposals 14 5%
Alter NIH proposals to avoid hESC research 11 4%
Consider relocation 9 3%
Disrupt collaborations 9 3%
The ten most common impacts reported by stem cell scientists are shown, based on qualitative
analysis of free-text responses describing the impact of ongoing policy uncertainty on scientists’
research plans. See Table S2 for example responses for each impact.
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uncertainty was impeding ongoing re-
search. This impact took several forms,
including increased cost and administra-
tive burden associated with returning to
the Bush Administration practice of
segregating federally and nonfederally
funded hESC research or conducting
research in duplicate with both hESCs
and IPSCs. Also notable, given the on-
going economic downturn and the inclu-
sion of research funding as part of the
financial stimulus plan, were economic
impacts noted by some scientists. In
particular, 24 scientists indicated that
the ongoing policy uncertainty made it
difficult to engage in long-term planning,
such as decisions to hire postdoctoral
researchers, graduate students, and
research technicians. In addition, a small
number of stem cell scientists indicated
that the ongoing uncertainty was leading
them to consider relocating tomore favor-
able research environments. Similar to the
impact of the temporary ban discussed
above, there was little evidence that
non-hESC scientists found this uncer-
tainty beneficial. Only 4 of the 87 respond-
ing non-hESC scientists who provided
a free-text description of the impact
described it as beneficial to their research
through increased prominence or funding
opportunities. In contrast, 6 of these non-
hESC scientists described a negative
impact on their research through, for
example, increased competition (presum-
ably from hESC scientists moving to non-
hESC work) or spillover effects between
various types of stem cell research. In134 Cell Stem Cell 8, February 4, 2011 ª2011addition, numerous non-hESC scientists
described other negative impacts, such
as hindered collaborations and changes
to their future research plans. These
results indicate that policy uncertainty
surrounding hESC research in the United
States has both negative scientific and
economic impacts and affects scientists
working with all types of stem cells.
The results reported here provide one
of the first systematic estimates of the
impact of the short-lived preliminary
injunction and ongoing policy uncertainty
on the conduct of stem cell research in
the United States. The results conflict
with Judge Lamberth’s assertion that
his preliminary injunction would have
little impact and suggest that rather
than simply preserving the status quo,
this injunction substantively changed
the playing field for many hESC scientists
in the United States as well as a lesser
number of stem cell scientists working
with other cell types. In addition, these
results indicate the broad impact of
ongoing policy uncertainty on the
research plans of stem cell scientists.
These results suggest that, regardless of
the ultimate outcome of the ongoing
legal proceedings, Judge Lamberth’s
ruling has already been a substantial
victory for opponents of hESC research.
The ruling increased the policy uncer-
tainty in the field at a time when many
scientists believed President Obama’s
policy offered respite from a lengthy
period of restricted funding and has
encouraged scientists to reconsider plans
to use hESCs in their research or acceler-Elsevier Inc.ated plans to transition away from these
cells. More surprisingly, these results
also suggest that the ruling and ongoing
policy uncertainty have negatively
affected non-hESC stem cell research,
a finding that likely runs counter to the
plaintiffs’ hopes.
While this analysis focused on stem cell
scientists in the United States, presum-
ably the scientists most affected by the
ongoing litigation, the nature of some of
the impacts reported—notably the dis-
ruption of collaborative research proj-
ects—suggests that this particular case
of policy uncertainty might also be
affecting stem cell scientists around the
world. Policy heterogeneity has previ-
ously been identified as a concern that
could hinder collaborative stem cell
research (Mathews et al., 2006), and this
analysis suggests that policy uncer-
tainty—essentially a form of policy hetero-
geneity over time—should also be consid-
ered a potential barrier to collaboration.
Policy uncertainty may also hinder
academic/industry collaborations and
limit access to venture funding, hindering
commercialization of hESC-based tech-
nologies (Harvey, 2009). Although the
current U.S. situation, where a lawsuit
threatens the legality of all federal hESC
funding, is a particularly dramatic case,
scientific uncertainty can arise in other
situations, and this analysis also high-
lights the types of impacts policymakers
around the world should consider when
crafting stem cell policies.
In addition to arguing for a reassess-
ment of the concept of harm to stem cell
scientists in the ongoing legal proceed-
ings, these findings suggest more broadly
that lawmakers, both in the United States
and around the world, aiming to support
stem cell research should strive for poli-
cies that, to the extent possible, reduce
uncertainty facing stem cell scientists. In
the United States, passing legislation to
provide a clear legal basis for the federal
funding of hESC research, thus pre-emp-
ting the ongoing legal proceedings and
reducing the field’s reliance on executive
action, would meet these goals. For indi-
vidual U.S. states as well as other jurisdic-
tions around the world developing stem
cell funding policies, adopting long-term
programs rather than relying on yearly
authorizations would seem a wise
strategy. Given the divisiveness of the
debate over hESC research and the
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charged areas, however, such policy
certainty will likely prove difficult to
achieve and some degree of uncertainty
may be unavoidable. For this reason,
hESC scientists should prepare to face
continued policy fluctuations, legal chal-
lenges, and other hurdles to their research
in the future.
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